SAGE THERAPEUTICS ($SAGE) posted quarterly earnings results on Tuesday, April 29th. The company reported earnings of -$1.01 per share, beating estimates of -$1.04 by $0.03. The company also reported revenue of $14,060,000, missing estimates of $14,402,971 by $-342,971.
You can see Quiver Quantitative's $SAGE stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SAGE THERAPEUTICS Hedge Fund Activity
We have seen 75 institutional investors add shares of SAGE THERAPEUTICS stock to their portfolio, and 81 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY added 3,785,557 shares (+468.0%) to their portfolio in Q4 2024, for an estimated $20,555,574
- CALIGAN PARTNERS LP added 3,052,538 shares (+inf%) to their portfolio in Q4 2024, for an estimated $16,575,281
- RTW INVESTMENTS, LP removed 2,589,330 shares (-46.3%) from their portfolio in Q4 2024, for an estimated $14,060,061
- STATE STREET CORP removed 1,653,589 shares (-56.5%) from their portfolio in Q4 2024, for an estimated $8,978,988
- BOOTHBAY FUND MANAGEMENT, LLC added 1,388,503 shares (+inf%) to their portfolio in Q4 2024, for an estimated $7,539,571
- FMR LLC removed 1,154,102 shares (-21.9%) from their portfolio in Q4 2024, for an estimated $6,266,773
- PALO ALTO INVESTORS LP removed 1,010,833 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $5,488,823
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
